Clinical trials: Esophageal Carcinoma
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006472
- Testing
- carboplatin, fluorouracil, paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Medstar Health Research Institute
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
This is a Phase 2, multi-cohort study to investigate safety, PK, and preliminary anti-tumor activity of the monoclonal antibody BGB A317 in combination with standard chemotherapy as first-line treatment.
- Trial name
- NCT03469557
- Testing
- Tislelizumab, Cisplatin, 5-FU
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- BeiGene
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Esophagus Cancer, Lung Cancer
Imaging Study Compare 4DCT Image
The goal of this clinical research study is to learn about ways to possibly reduce scanning errors when using 4-dimensional computed tomography (4D CT) scans to check lung function in patients with esophageal or lung cancer.
- Trial name
- NCT01626001
- Testing
- 4D CT scans
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Barrett Esophagus, Esophageal Cancer
Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions
To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there is a need for better endoscopic visualization…
- Conditions
- Barrett Esophagus, Esophageal Cancer, Dysplasia in Barrett Esophagus
- Trial name
- EAGLE (NCT03205501)
- Testing
- IV-administation of EMI-137, Molecular Fluorescence Endoscopy platform
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Esophageal Neoplasms
Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
There is no standard treatment strategy for recurrent or metastatic esophageal squamous cell carcinoma patients now, especially after the second-line treatment.
- Trial name
- NCT03274011
- Testing
- Apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Esophageal Cancer
A Comparison Between Ivor-Lewis and McKeown Minimally Invasive Esophagectomy
Surgery is still the main treatment for esophageal cancer, however, the complication and mortality rate of open esophagectomy is high.
- Trial name
- NCT04217239
- Testing
- MIE Ivor- Lewis, MIE McKeown
- Where
- China
- Volunteers
- 272 people
- Sponsor
- The Second Hospital of Shandong University
Esophageal Cancer
Large-scale Models of Esophageal Cancer and Related Research
The goal of this observational study is to learn about the clinical utility of an artificial intelligence (AI) large language model in patients undergoing screening, diagnosis, treatment, and prognosis assessment for esophageal…
- Trial name
- DeepDT (NCT07642401)
- Testing
- Observational study; no assigned intervention. Participants receive routine esophageal cancer management (endoscopy, imaging, pathology, clinical follow-up) as standard care.
- Where
- 3 sites in China
- Volunteers
- 12,000 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Squamous Cell Carcinoma
Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
This prospective observational cohort study will evaluate different radiotherapy target volume delineation patterns in patients with locally advanced esophageal squamous cell carcinoma receiving radiotherapy combined with…
- Trial name
- NCT07858630
- Testing
- GTV-CTV Longitudinal Margin, Regional Lymph Node Irradiation Strategy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
- Conditions
- Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Trial name
- eVOLVE-02 (NCT06535607)
- Testing
- Volrustomig, Cisplatin, Carboplatin
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Esophageal Cancer
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal…
- Trial name
- NCT00393068
- Testing
- Erlotinib, Bevacizumab, Paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- SCRI Development Innovations, LLC
Esophageal Neoplasm
A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer
This study is for patients with esophageal cancer that has spread to other areas. The purpose of this study is to: 1. Determine how well a combination of taxol, UFT, and leucovorin work in these patients, 2.
- Trial name
- NCT00037089
- Testing
- UFT (Tegafur/Uracil)
- Where
- United States
- Sponsor
- Edelman, Martin, M.D.
Locally Advanced Esophageal Squamous Cell Carcinoma
The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT03917966
- Testing
- SHR-1210+docetaxel+nedaplatin, SHR-1210+Apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Cancer Stage III
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Background The promising therapeutic outcomes of neoadjuvant chemoimmnotherapy in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase II clinical trials and have been…
- Trial name
- NCT06965829
- Testing
- Tislelizumab, Carboplatin and Paclitaxel and Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Cancer, Chemoradiotherapy
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
This trial is a prospective, randomized, controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of sintilimab as consolidation therapy in elderly patients with esophageal cancer who did not progress…
- Conditions
- Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
- Trial name
- NCT06413342
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Zhejiang Cancer Hospital
Radiotherapy; Complications, Cardiotoxicity
Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients
The purpose of this study is to evaluate and compare the changes by two modalities: Imaging by Strain by Speckle Tracking and Magnetic Resonance versus soluble markers of cardiac dysfunction as early predictors of cardio-toxicity…
- Conditions
- Radiotherapy; Complications, Cardiotoxicity, Cancer, Lung Cancer
- Trial name
- NCT04896242
- Where
- Chile
- Volunteers
- 47 people
- Sponsor
- Pontificia Universidad Catolica de Chile
EUS Guided Cyanoacrylate Injection, Endoscopic Variceal Band Ligation
EUS Glue vs Endoscopic Variceal Band Ligation for Prevention of Rebleeding in Patients With HCC and EV Bleeding: a Retrospective Comparative Study
SP by EUS-CYA improves clinical outcomes (eg, EV rebleeding) in patients with HCC and prior EV bleeding when compared with SP by EGD-VBL
- Conditions
- EUS Guided Cyanoacrylate Injection, Endoscopic Variceal Band Ligation, Hepatocelular Carcinoma, Esophageal Variceal Bleeding
- Trial name
- EUSgluevsVBL (NCT04918459)
- Where
- Hong Kong
- Volunteers
- 70 people
- Sponsor
- Chinese University of Hong Kong
Esophageal Cancer, Endostatin
Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.
Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in esophageal cancer.This study aims at assessing the efficacy and safety of endostatin combined with…
- Trial name
- NCT02745561
- Testing
- Endostatins, Oxaliplatin, Radiotherapy
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Hangzhou Cancer Hospital
Bronchogenic Carcinoma
A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST)
In the UK, staging of lung cancer is time consuming (taking on average more than 3 weeks), costly and inaccurate in up to 20% of cases.
- Trial name
- BOOST (NCT00652769)
- Testing
- Endobronchial or Endoscopic Ultrasound, Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy
- Where
- 4 sites in United Kingdom
- Volunteers
- 168 people
- Sponsor
- University College London Hospitals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.